Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study - Scorecard - MDSpire

Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study

  • By

  • Laura Mühlhausen

  • Martin Kocher

  • Hanah Hadice Karadachi

  • Ulrich Sure

  • Yahya Ahmadipour

  • Levin Häni

  • Danial Nasiri

  • Tommaso Araceli

  • Martin Proescholdt

  • Nils Ole Schmidt

  • Andrea Cattaneo

  • Vera Nickl

  • Florian Scheichel

  • Franz Marhold

  • Stefan J. Grau

  • Christina A. Hamisch

  • Franz L. Ricklefs

  • Yahya Zghaibeh

  • Roland H. Goldbrunner

  • Stephanie T. Jünger

  • July 10, 2026

  • 0 min

Share

Clinical Scorecard: Outcomes of Leptomeningeal Disease Following Brain Metastasis Resection: Findings from the Multicenter SUBAROMA Trial

At a Glance

CategoryDetail
ConditionLeptomeningeal Disease (LMD)
Key MechanismsDissemination of tumor cells along the leptomeninges and cerebrospinal fluid (CSF).
Target PopulationPatients with systemic cancer who develop brain metastases.
Care SettingMulticenter neurosurgical departments in Germany, Austria, and Switzerland.

Key Highlights

  • Up to 30% of patients with systemic cancer develop brain metastases.
  • LMD is associated with poor prognosis and reduced overall survival.
  • High overall disease burden and anatomical location of BM are predictors of LMD.
  • Postoperative radiation therapy type influences LMD risk.
  • The study aims to identify risk factors for LMD development.

Guideline-Based Recommendations

Diagnosis

  • LMD diagnosed by MRI and/or CSF sampling.

Management

  • Surgery indicated for neurological symptoms caused by BM.

Monitoring & Follow-up

  • Regular clinical assessment and MRI follow-up.

Risks

  • Piecemeal resection and intraoperative access to ventricles increase LMD risk.

Patient & Prescribing Data

Patients aged ≥ 18 years undergoing surgery for brain metastases.

Systemic therapy continued or initiated based on extracranial tumor manifestation.

Clinical Best Practices

  • Utilize state-of-the-art surgical techniques for BM resection.
  • Assess extent of resection using postoperative MRI.
  • Implement interdisciplinary tumor board discussions for surgical indications.

Related Resources & Content

Original Source(s)

Leptomeningeal disease (LMD) after resection of brain metastases: results of the multicenter SUBAROMA study

  • by Laura Mühlhausen, Martin Kocher, Hanah Hadice Karadachi, Ulrich Sure, Yahya Ahmadipour, Levin Häni, Danial Nasiri, Tommaso Araceli, Martin Proescholdt, Nils Ole Schmidt, Andrea Cattaneo, Vera Nickl, Florian Scheichel, Franz Marhold, Stefan J. Grau, Christina A. Hamisch, Franz L. Ricklefs, Yahya Zghaibeh, Roland H. Goldbrunner, Stephanie T. Jünger

  • July 10, 2026

Related Content

Inside the Rise of circRNA

Circio CEO Erik Wiklund reflects on the discovery of human circular RNA and its evolution into a fast-moving therapeutic modality

  • July 9, 2026

  • 12 min
Retraction Note: Multi-omics analysis of genomics, epigenomics and transcriptomics for molecular subtypes and core genes for lung adenocarcinoma

Impact of tumor immunotherapy on kidney injury and multi-organ outcomes: a mechanistic and clinical perspective